The Pharmaceutical Research Institute of Haosen Pharmaceutical Group has a number of technical platforms, such as chemical development, biological development, preparation development, process research and pilot research. It is the national recognized enterprise technology center and the main undertaker of some projects of the National 863 Plan. Haosen Pharmaceutical Group attaches great importance to product quality, with advanced international manufacturing and testing equipment, lean manufacturing technology and strict quality management system. All preparation production lines have passed gmp certification. All API production lines have passed the official certification of fda, epdm, Japan and South Korea. The Institute has always maintained close cooperation and technical exchanges with well-known pharmaceutical research institutions at home and abroad, and many research projects have always been at the forefront of industry technology. In 26, Post-Doctoral Research Center was established with the approval of the Ministry of Personnel. The Institute has always maintained close cooperation and technical exchanges with well-known pharmaceutical research institutions at home and abroad, and many research projects have always been at the forefront of industry technology. Among them, the research and development of anti-tumor and diabetes drugs has been approved by the "National Major New Drug Creation Project". At present, the Institute has applied for or obtained nearly 2 compound patents, and a number of national first-class new drugs with independent intellectual property rights have entered clinical research, showing good effectiveness and safety, and some products are expected to be put on the market in recent years. In 27, it was awarded as "Demonstration Enterprise of Drug Quality Integrity Construction" by China Pharmaceutical Quality Management Association.
In the future, Hausen will adhere to the enterprise purpose of "serving the society and creating health", and make a new step in scientific and technological innovation, sales network and talent team construction, accelerate its growth into a first-class pharmaceutical group in China, and make greater contributions to the pharmaceutical industry in China and the health of human beings.
Legal representative: Zhong Huijuan
Date of establishment: 2-1-5
Registered capital: 5 million yuan
Location: Jiangsu Province
Unified social credit code: 9132772421193r
Operating status: in business
. Investment consulting; Investment management; Information transmission. (Projects subject to approval according to law can only be operated after approval by relevant departments)